

## ASX ANNOUNCEMENT

### W.H.O. GDP CERTIFICATION ACHIEVED AT DISTRIBUTION CENTRES AND JV UPDATE

26 JULY 2023

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Company**) is pleased to announce that World Health Organisation (**WHO**) Good Distribution Practices certification has been achieved at the Company's Gold Coast and Melbourne Distribution Centres and to also provide an update on recently formed joint ventures.

#### World Health Organisation Good Distribution Practices certification achieved

On 25 July 2023, the Company achieved the Good Distribution Practices (**GDP**) certification of its Gold Coast (GDC) and Melbourne (MDC) Distribution Centres meeting the requirements outlined by the World Health Organisation.

Maintaining product safety and quality during distribution is of utmost importance in the pharmaceutical industry. GDP Certification for Pharmaceuticals demonstrates Vitura's dedication to good distributive practices and quality in every aspect of our service.

GDP is a quality system for warehouse and distribution centres dedicated for medicines. Internationally accepted pharmaceutical GDP regulations, including issues such as storage and handling, stipulate that distributors of pharmaceutical products must align their operations with the standards. A voluntary independent assessment of compliance against international GDP requirements has established that Vitura's quality management system complies with GDP requirements.

Following rigorous training and inspection over an extended period, the certifications were recently granted. This was another team effort, and Vitura thanks the continued dedication and effort of the staff who delivered this significant outcome.

#### Cortexa Joint Venture

On 2 May 2023, the Company announced its JV with PharmAla Biotech Holdings Inc. (**PharmAla**, CSE:MDMA) to form Cortexa, in order to become the leading supplier of MDMA and psilocybin in the Australian market following regulatory change by the Therapeutic Goods Administration (**TGA**) on 3 February 2023.

Since Cortexa was formed, it has placed an order with PharmAla for GMP grade MDMA and psilocybin – both bulk material for local manufacturing and patient ready product for prescription via the TGA's Authorised Prescriber Scheme. Additionally, Cortexa has recruited a full time Medical Business Development Manager who is in field engaging with psychiatrists and clinical trial sites in relation to future supply and orders.



The first order of MDMA and psilocybin is expected to be delivered to one of Vitura's Distribution Centres in September. This will coincide with the first PTSD and treatment resistant depression patients expected to be prescribed MDMA or psilocybin, respectively, by Authorised Prescriber psychiatrists in late September.

Finally, Cortexa is in final negotiations with a local contract manufacturer for production of GMP patient-ready MDMA and psilocybin capsules, which is expected to be completed by mid-August.

The Company looks forward to continuing to provide updates on Cortexa's progress.

### **Releaf Joint Venture**

On 16 May 2023, the Company announced its unincorporated JV with Releaf Group Limited (**Releaf**) to combine the leading technology and distribution capabilities of Vitura through the CanView platform and the large network of franchise medical cannabis clinical services of Releaf.

The Releaf branded version of the CanView Pharmacy App has been completed and has been rolled out in the four established Releaf dispensaries. The Releaf branded version of the CanView Doctor App and Patient App is planned for release in the coming weeks. This is expected to drive additional volume of medicinal cannabis prescriptions through the CanView platform.

The Company looks forward to continuing to provide updates on the progress of the JV with Releaf.

**\*\* ENDS \*\***



## About Vitura Health Limited (ASX:VIT)

Vitura Health Limited is listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 260+ product SKUs within Australia from 39 international and domestic medicinal cannabis brands.
  - CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The CanView system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up CanView, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, CanView provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the CanView platform, without the need to input the patient's details. Prescriptions are then sent directly to the CanView patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the 3,600+ Australian pharmacies with accounts on CanView for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4 and 8. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

[www.vitura.com.au](http://www.vitura.com.au)

[www.canview.com.au](http://www.canview.com.au)

[www.burleighheadscannabis.com](http://www.burleighheadscannabis.com)

[www.cortexa.com.au](http://www.cortexa.com.au)

[www.cdaclinics.com.au](http://www.cdaclinics.com.au)

[www.cannadoc.com.au](http://www.cannadoc.com.au)



**Authorised by**

Rodney Cocks, Chief Executive Officer and Executive Director

**Contact**

**Vitura Health Limited**

Rodney Cocks

Chief Executive Officer and Executive Director

1300 799 491

[info@vitura.com.au](mailto:info@vitura.com.au)

**Media enquiries**

Tim Fogarty

The Civic Partnership

+61 400 179 075

[tim.fogarty@civicpartners.com.au](mailto:tim.fogarty@civicpartners.com.au)

**Forward-looking statements**

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.